CA2455341A1 - Novel ligand for nicotinic acetylcholine receptors useful in therapy - Google Patents
Novel ligand for nicotinic acetylcholine receptors useful in therapy Download PDFInfo
- Publication number
- CA2455341A1 CA2455341A1 CA002455341A CA2455341A CA2455341A1 CA 2455341 A1 CA2455341 A1 CA 2455341A1 CA 002455341 A CA002455341 A CA 002455341A CA 2455341 A CA2455341 A CA 2455341A CA 2455341 A1 CA2455341 A1 CA 2455341A1
- Authority
- CA
- Canada
- Prior art keywords
- prophylaxis
- treatment
- disease
- compound
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29520601P | 2001-06-01 | 2001-06-01 | |
| US60/295,206 | 2001-06-01 | ||
| PCT/SE2002/001031 WO2002096912A1 (en) | 2001-06-01 | 2002-05-29 | Novel ligand for nicotinic acetylcholine receptors useful in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2455341A1 true CA2455341A1 (en) | 2002-12-05 |
Family
ID=23136711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002455341A Abandoned CA2455341A1 (en) | 2001-06-01 | 2002-05-29 | Novel ligand for nicotinic acetylcholine receptors useful in therapy |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1397366B1 (enExample) |
| JP (1) | JP2004532877A (enExample) |
| KR (1) | KR20040003021A (enExample) |
| CN (1) | CN1294136C (enExample) |
| AT (1) | ATE353332T1 (enExample) |
| BR (1) | BR0210075A (enExample) |
| CA (1) | CA2455341A1 (enExample) |
| DE (1) | DE60218032T2 (enExample) |
| DK (1) | DK1397366T3 (enExample) |
| ES (1) | ES2280538T3 (enExample) |
| IL (1) | IL158735A0 (enExample) |
| MX (1) | MXPA03010996A (enExample) |
| NO (1) | NO20035333D0 (enExample) |
| NZ (1) | NZ529426A (enExample) |
| PT (1) | PT1397366E (enExample) |
| SI (1) | SI1397366T1 (enExample) |
| WO (1) | WO2002096912A1 (enExample) |
| ZA (1) | ZA200308779B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| AU2003224545B2 (en) | 2002-04-18 | 2009-08-13 | Astrazeneca Ab | Thienyl compounds |
| MXPA04010190A (es) | 2002-04-18 | 2005-02-03 | Astrazeneca Ab | Compuestos heterociclicos. |
| CN1325500C (zh) | 2002-04-18 | 2007-07-11 | 阿斯特拉曾尼卡有限公司 | 呋喃基化合物 |
| KR20060094962A (ko) * | 2003-10-21 | 2006-08-30 | 아스트라제네카 아베 | 스피로푸로피리딘 아릴 유도체 |
| TW200813067A (en) | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| RS52703B (sr) | 2008-06-20 | 2013-08-30 | Astrazeneca Ab | Derivat dibenzotiazepina i njegova upotreba |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| PT3029039T (pt) | 2010-05-17 | 2017-11-28 | Forum Pharmaceuticals Inc | Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| EP2846796A4 (en) | 2012-05-08 | 2015-10-21 | Forum Pharmaceuticals Inc | METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| JP6478923B2 (ja) | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート |
| EA029430B1 (ru) | 2013-06-21 | 2018-03-30 | Такеда Фармасьютикл Компани Лимитед | Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA984637B (en) * | 1997-05-30 | 1998-12-21 | Neurosearch As | Spiro-quinuclidine derivatives their preparation and use |
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
-
2002
- 2002-05-29 CN CNB028110498A patent/CN1294136C/zh not_active Expired - Fee Related
- 2002-05-29 ES ES02731063T patent/ES2280538T3/es not_active Expired - Lifetime
- 2002-05-29 JP JP2003500091A patent/JP2004532877A/ja active Pending
- 2002-05-29 KR KR10-2003-7015462A patent/KR20040003021A/ko not_active Ceased
- 2002-05-29 DK DK02731063T patent/DK1397366T3/da active
- 2002-05-29 MX MXPA03010996A patent/MXPA03010996A/es active IP Right Grant
- 2002-05-29 BR BR0210075-4A patent/BR0210075A/pt not_active IP Right Cessation
- 2002-05-29 CA CA002455341A patent/CA2455341A1/en not_active Abandoned
- 2002-05-29 SI SI200230510T patent/SI1397366T1/sl unknown
- 2002-05-29 DE DE60218032T patent/DE60218032T2/de not_active Expired - Fee Related
- 2002-05-29 AT AT02731063T patent/ATE353332T1/de not_active IP Right Cessation
- 2002-05-29 EP EP02731063A patent/EP1397366B1/en not_active Expired - Lifetime
- 2002-05-29 IL IL15873502A patent/IL158735A0/xx unknown
- 2002-05-29 NZ NZ529426A patent/NZ529426A/en unknown
- 2002-05-29 WO PCT/SE2002/001031 patent/WO2002096912A1/en not_active Ceased
- 2002-05-29 PT PT02731063T patent/PT1397366E/pt unknown
-
2003
- 2003-11-11 ZA ZA200308779A patent/ZA200308779B/en unknown
- 2003-11-28 NO NO20035333A patent/NO20035333D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20035333D0 (no) | 2003-11-28 |
| IL158735A0 (en) | 2004-05-12 |
| EP1397366A1 (en) | 2004-03-17 |
| BR0210075A (pt) | 2004-08-17 |
| ZA200308779B (en) | 2005-02-11 |
| CN1512995A (zh) | 2004-07-14 |
| DK1397366T3 (da) | 2007-05-07 |
| PT1397366E (pt) | 2007-04-30 |
| DE60218032T2 (de) | 2007-08-16 |
| MXPA03010996A (es) | 2004-02-27 |
| HK1063787A1 (en) | 2005-01-14 |
| ATE353332T1 (de) | 2007-02-15 |
| DE60218032D1 (de) | 2007-03-22 |
| WO2002096912A1 (en) | 2002-12-05 |
| EP1397366B1 (en) | 2007-02-07 |
| SI1397366T1 (sl) | 2007-06-30 |
| CN1294136C (zh) | 2007-01-10 |
| KR20040003021A (ko) | 2004-01-07 |
| NZ529426A (en) | 2005-07-29 |
| JP2004532877A (ja) | 2004-10-28 |
| ES2280538T3 (es) | 2007-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1213291B1 (en) | Spiro [1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine for use in the treatment of psychotic and intellectual impairment disorders | |
| EP1397366B1 (en) | Novel ligand for nicotinic acetylcholine receptors useful in therapy | |
| EP0777671B1 (en) | Spiro-azabicyclic compounds useful in therapy | |
| US7417050B2 (en) | Heterocyclic compounds | |
| US7417049B2 (en) | Furyl compounds | |
| US20070142419A1 (en) | Thienyl Compounds | |
| US6569865B2 (en) | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine | |
| AU2004285751B2 (en) | Spirofuropyridine aryl derivatives | |
| AU2002303064A1 (en) | Novel ligand for nicotinic acetylcholine receptors useful in therapy | |
| HK1063787B (en) | Novel ligand for nicotinic acetylcholine receptors useful in therapy | |
| US20070244097A1 (en) | Nicotinic AcetylcholineReceptor Ligands | |
| ZA200604018B (en) | 4-Substituted imidazoles | |
| HK1010370B (en) | Spiro-azabicyclic compounds useful in therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |